Abstract:As angiogenesis plays a key role in tumor growth and metastasis, the angiogenic process has attracted scientific interest as a target for diagnostic and therapeutic agents. Factors influencing angiogenesis include the vascular endothelial growth factor (VEGF) family and the two associated receptor types (VEGFR-1 and VEGFR-2). VEGFR-1/-2 detection and quantification in cancer lesions are essential for tumor process management. As a result of the advantageous pharmacokinetics and image contrast, peptides radiolabeled with PET emitters have become interesting tools for the visualization of VEGFR-1/-2-positive tumors. In this study, we prepared 68Ga-labeled peptides containing 15 (peptide 1) and 23 (peptide 2) amino acids as new PET tracers for tumor angiogenic process imaging. Methods: The peptides were conjugated with NODAGA-tris(t-Bu ester) and subsequently radiolabeled with [68Ga]Ga-chloride. The prepared [68Ga]Ga-NODAGA-peptide 1 and [68Ga]Ga-NODAGA-peptide 2 were tested for radiochemical purity and saline/plasma stability. Consequently, the binding affinity toward VEGFRs was assessed in vitro on human glioblastoma and kidney carcinoma cells. The found peptide receptor affinity was compared with the calculated values in the PROtein binDIng enerGY prediction (PRODIGY) server. Finally, the biodistribution study was performed on BALB/c female mice to reveal the basic pharmacokinetic behavior of radiopeptides. Results: The in vitro affinity testing of [68Ga]Ga-NODAGA-peptides 1 and 2 showed retained receptor binding as characterized by equilibrium dissociation constant (KD) values in the range of 0.5-1.2 μM and inhibitory concentration 50% (IC50) values in the range of 3.0-5.6 μM. Better binding properties of peptide 2 to VEGFR-1/-2 were found in the PRODIGY server. The biodistribution study on mice showed remarkable accumulation of both peptides in the kidneys and urinary bladder with a short half-life after intravenous application. The in vitro plasma stability of [68Ga]Ga-NODAGA-peptide 2 was superior to that of [68Ga]Ga-NODAGA-peptide 1. Conclusions: The obtained results demonstrated a high radiolabeling yield with no need for purification and preserved binding potency of 68Ga-labeled peptides 1 and 2 toward VEGFRs in cancer cells. The peptide-receptor protein interaction assessed in protein-peptide docking determined the strongest interaction of peptide 2 with domain 2 of VEGFR-2 in addition to a more acceptable plasma stability (t1/2 = 120 min) than that for peptide 1. We found both radiolabeled peptides very potent in their receptor binding, which makes them suitable imaging agents. The rapid transition of the radiopeptides into the urinary tract indicates suitable pharmacokinetic characteristics.

Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Identification of a High Affinity TAG-72 Binding Peptide by Phage Display Selection

A New TAG-72 Cancer Marker Peptide Identified by Phage Display

A Ga-68 Labeled Peptide for Imaging of {alpha}v{beta}6 Positive Tumor

Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging

Preparation, In Vitro Affinity, and In Vivo Biodistribution of Receptor-Specific 68Ga-Labeled Peptides Targeting Vascular Endothelial Growth Factor Receptors

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display

A Direct Comparison of Tumor Angiogenesis with 68 Ga-labeled NGR and RGD Peptides in HT-1080 Tumor Xenografts Using Micropet Imaging

Preclinical Study of a Dual-Target Molecular Probe Labeled with 68Ga Targeting SSTR2 and FAP

Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake

Comparative Studies of Three 68Ga-Labeled [Des-Arg10]kallidin Derivatives for Imaging Bradykinin B1 Receptor Expression with PET.

2-Mercaptoacetylglycylglycyl (MAG2) As a Bifunctional Chelator for 99Mtc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics

Application of a new 68Ga-labeled cNGR dimer peptide to microPET imaging of ovarian cancer

Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.

Evaluation of A Cu-64-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for Pet of Tumors Expressing Alpha(V)Beta(3) Integrin

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

A Uniquely Modified DKL-based Peptide Probe for Positron Emission Tomography Imaging

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer

HaloTag As a Reporter Gene: Positron Emission Tomography Imaging with (64)Cu-Labeled Second Generation HaloTag Ligands.